Timber Pharmaceuticals Stock Price, News & Analysis (NYSE:TMBR)

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares.
View TMBR analyst ratings or view top-rated stocks.

1 brokerages have issued 12 month target prices for Timber Pharmaceuticals' stock. Their TMBR share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year.
View analysts price targets for TMBR or view top-rated stocks among Wall Street analysts.

Timber Pharmaceuticals's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Timber Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Tudor Investment Corp Et Al (7.32%). Insiders that own company stock include Alan Mendelsohn, Edward J Sitar, John Koconis and Tardimed Sciences Llc.
View institutional ownership trends.

Shares of TMBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.